Translational studies on immunologic biomarkers and precision therapy in ovarian and breast cancer

Author(s):
Groot, A.F. de
Published
2026
Publication type
Doctoral Thesis

Abstract

This thesis focusses on translational studies in patients with both EOC and BC and consists of two main parts. In part 1, immunological markers in both EOC and BC were studied, with the ultimate goal to find markers which can serve as predictors for therapy response in the future. The second part focusses on CDK4/6i in (early) BC, which aim to prevent tumor cell proliferation by inhibiting CDK4/6, thereby blocking cell cycle progression.

Ealy breast cancerEpithelial ovarian cancermMDSC to DC ratioCDK4/6 inhibitionRibociclibBiomarkersImmunotherapyTargeted therapyNEOLBC trial
Defense date
2026-05-26
Language
English
Supervisor(s)
Burg, S.H. van der; Kroep, J.R.
Committee member(s)
Mirande, N.F. de; Poelgeest, M.I.E. van; Portielje, J.E.A.; Kok, M.; Nijman, H.W.
Qualification
Ph.D.
Degree granting institution
Faculty of Medicine, Leiden University Medical Center (LUMC), Leiden University, Leiden
hdl
1887/4303955

Funding

Sponsorship
The PITCH and CHIP study were supported by the Bontius Stichting;The NEOZOTAC study was supported by a grant from the Dutch Cancer Society (2010–4682); The NEOLBC study was supported by unrestricted grants from Philips and Novartis; The printing of this thesis was financially supported by the Department of Medical Oncology of the Leiden University Medical Center